Surveilling Middle-Risk Prostate Cancer: Cautionary Data

February 15, 2017

A new study published in the December 2016 issue of the Journal of Urology indicates that active surveillance (AS) may not be a recommended treatment option for men with intermediate-risk prostate cancer.

 

Active surveillance is a NICE recommended treatment option for many incidents of prostate cancer. And, despite earlier research finding no significant difference in progression- free survival in low- and intermediate-risk populations, the new study conducted by the Sunnybrooke Health Sciences Centre and University of Toronto, Ontario, Canada, is significant because it has found a patient’s Gleason score to be an important factor in his 15-year metastasis-free survival (MFS) rate.

 

This evidence suggests that patients with a Gleason score of 7 are likely to suffer greater adverse outcomes through active surveillance in comparison to those with a Gleason score of 6 or less, and recommends that "Active surveillance for patients with Gleason 7 disease should be offered only in the setting of a clinical study," according to Hima Bindu Musunuru, MD.

 

For the full editorial extract, click here

 

 

 

 

 

 

Please reload

Recent Posts
Please reload

Archive
Please reload

Search By Tags
Please reload

Follow Us
  • LinkedIn Social Icon
  • Facebook Basic Square
  • Twitter Basic Square

Registered Address: The Coach House, Grenville Court, Britwell Road, Burnham, SL1 8DF

Company Registration No: 08252168

  • Black Facebook Icon
  • Black Twitter Icon
  • Black LinkedIn Icon
  • Black YouTube Icon